More Medicare Deals Close in May

More Medicare Deals Close in May

In late April, the Social Security and Medicare Trustees released two reports on the financial state of their respective programs, and you’ve probably guessed, the outlook is grim. Without accounting for the adverse economic or health consequences of COVID-19, the organizations find Medicare Part A, which covers inpatient hospital care, skilled nursing facility, hospice, lab tests, surgery, and home health care, will face insolvency in six years. Considering COVID-19 is dealing heavy blows to healthcare services as a whole, it’s fair to say the pandemic is draining funds even faster. However, there is temporary relief for the market. The CARES Act passed by Congress promised... Read More »
Magellan Sells Complete Care to Molina

Magellan Sells Complete Care to Molina

Easy come, easy go. Magellan Health, Inc. (NASDAQ: MGLN) is selling its Magellan Complete Care (MCC) business to Monlina Healthcare, Inc. (NYSE: MOH). The cash purchase price, according to Magellan, is $850 million. According to Molina, it is paying approximately $820 million, net of certain tax benefits. MCC, which had revenue of more than $2.7 billion in 2019 and approximately 155,000 members, manages full-service Medicaid and Medicare health plans including Magellan Complete Care in Arizona, Florida, and Virginia; Senior Whole Health in Massachusetts and New York; and TMG by Magellan in Wisconsin. It wasn’t that long ago (well, July 2017) that Magellan paid $400 million to buy... Read More »
Hot Healthcare Sectors for Investment, Growth & Consolidation in 2020

Hot Healthcare Sectors for Investment, Growth & Consolidation in 2020

Every year, starting in November, the crystal balls come out and the prognostications begin. What will the new year bring? Who or what will make out better and who or what will not? We talked with Gary Herschman, a member of Epstein Becker Green’s Healthcare and Life Sciences practice, about the healthcare sectors he and his firm are watching in 2020. Here are their predictions for 2020. Health Care M&A: What do you see as the biggest themes in the healthcare industry this year? There are a lot of moving parts, from the discovery of new drugs to the shifting attention to post-acute care. Gary Herschman: We see three key “drivers” of health industry transformation that are already... Read More »
2019’s Biggest Healthcare Deals, by Sector

2019’s Biggest Healthcare Deals, by Sector

2020 has just begun, which means it’s time to look back at the healthcare M&A landscape of 2019. Just three days into the new year, nearly 1,780 deals are already on the books for 2019. More deals will turn up as we search our many sources, but the number likely won’t top the record of 1,900-plus set in 2018. Thanks to the multi-billion-dollar deals announced in the Biotech and Pharmaceutical sectors, 2019 will set a new spending record. Preliminary data show $399.1 billion was spent on healthcare acquisitions last year, about 20% higher than in 2018. We expect that number to rise as we go through the year and the 10Ks and quarterly reports come out. It’s possible the... Read More »
Humana Doubles Down on Hospice Services

Humana Doubles Down on Hospice Services

Humana Inc. (NYSE: HUM) is moving more deeply into hospice care with its recent announcement that it will acquire Philadelphia-based Enclara Healthcare from Consonance Capital Partners and Enclara management. Enclara is one of the largest hospice and pharmacy benefit management (PBM) providers in the country, serving 450 hospice providers and 97,000 hospice patients daily. This deal includes mail-order pharmacy Enclara Pharmacia, specialty PBM GuidantRx and pharmacy Avanti Health Care Services. Enclara’s palliative care provider, Turn-Key Health, is not included. Consonance first invested in Enclara in 2014 and added ExcelleRx, PGM Holdings and Avanti Health Care Services in the... Read More »
More Medicare Deals Close in May

Diplomat Pharmacy, under Pressure, Merges with OptumRx

In early November, Diplomat Pharmacy, Inc. (NYSE: DPLO) revealed some troubling news. The company reported a net loss of $177.3 million in its third-quarter earnings report, its third in a row, and issued a “going concern” warning. Shares dropped 50% (from $6.20 to $3.10) that morning. Brian Griffin, chairman and CEO of Diplomat, cited industry headwinds pressuring its prescription benefits management (PBM) business, and its failure to renew network participation in their specialty pharmacy network. Diplomat’s PBM segment generated $82 million in Q3:19, compared to $170 million in the same quarter last year. Diplomat Pharmacy’s efforts to expand in the PBM sector... Read More »